Summary by Correspondence Anatoly & E. Martynyuk
doi:10.1093/brain/awh354 Brain Page 1 of 8
Long-term changes in glutamatergic synaptic
transmission in phenylketonuria
A. V. Glushakov,
1 O. Glushakova,
2 M. Varshney,
1 L. K. Bajpai,
1 C. Sumners,
3,6 P. J. Laipis,
4
J. E. Embury,
4 S. P. Baker,
5 D. H. Otero,
5 D. M. Dennis,
1,6 C. N. Seubert
1 and A. E. Martynyuk
1,6
Correspondence to: Anatoly E. Martynyuk, PhD,
Department of Anesthesiology, University of Florida,
P.O. Box 100254, JHMHC, 1600 SW Archer Road,
Gainesville, FL 32610-0254, USA
E-mail: AMartynyuk@anest.uﬂ.edu
Departments of
1Anesthesiology,
2Medicine,
3Physiology
and Functional Genomics,
4Biochemistry and Molecular
Biology and
5Pharmacology and Therapeutics and
6McKnight Brain Institute, University of Florida,
Gainesville, FL, USA
Summary
The cellular mechanisms that underlie impaired brain
function during phenylketonuria (PKU), the most com-
mon biochemical cause of mental retardation in humans,
remain unclear. Acute application of L-Phe at concentra-
tions observed in the PKU brain depresses glutamatergic
synaptic transmission but does not affect GABA receptor
activity in cultured neurons. If these depressant effects of
L-Phe take place in the PKU brain, then chronic impair-
ment of the glutamate system, which may contribute to
impaired brain function, could be detected as changes in
postsynaptic glutamate receptors. This hypothesis was
tested by using a combination of liquid chromatography–
mass spectrometry, patch-clamp, radioligand binding and
western blot approaches in forebrain tissue from hetero-
zygous and homozygous (PKU) Pah
enu2 mice. Brain con-
centrations of L-Phe were nearly six-fold greater in PKU
mice (863.12 6 17.96 mmol/kg) than in their heterozygous
counterparts (149.32 6 10.23 mmol/kg). This concentra-
tionissigniﬁcantlyhigherthantheKBof573mMforL-Phe
to compete for N-methyl-D-aspartate (NMDA) receptors.
Receptor binding experiments with [
3H]MK-801 showed
signiﬁcant up-regulation of NMDA receptor density in
PKU mice. Consistent with the depressant effects of
L-Phe, expression of NMDA receptor NR2A and
(RS)–amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptor Glu1 and Glu2/3 subunits was signiﬁc-
antly increased, whereas expression of the NR2B subunit
was decreased. There was no change in GABA a1 subunit
expression. Given the role of the glutamatergic system
in brain development and function, these changes may, at
least in part, explain the brain disorders associated with
PKU.
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Introduction
Glutamate, the main excitatory neurotransmitter, plays a cru-
cial role in brain development and function (Johnston, 2003).
Growing evidence indicates that impaired glutamatergic
synaptic transmission may contribute to a diverse group of
paediatric neurological disorders (e.g. fragile X syndrome,
Rett syndrome, epilepsy) (Johnston, 2003; Loftis and
Janowsky, 2003). Establishment of abnormalities of glutama-
tergic signalling in each disease state and elucidation of the
molecular and cellular mechanisms mediating these altera-
tions is important not only for developing novel therapeutic
strategiesbutalsoforunderstandingtherolesofglutamatergic
synaptic transmission in brain functioning. This process is
often complicated by the pathogenic complexity in many
diseases. For a number of reasons, phenylketonuria (PKU)
is an ideal model to investigate such mechanisms. PKU
represents the most common biochemical cause of brain
disorder in humans. Importantly, the cause of PKU is simple
and its starting point is well-deﬁned: namely, the elevated
concentrations of the aromatic amino acid phenylalanine
(L-Phe), which occur immediately after birth (Scriver and
Kaufman, 2001). Furthermore, there is a murine model for
PKU (Pah
enu2 mice) that closely resembles the metabolic and
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 neurobiological phenotype of human PKU (Zagreda et al.,
1999; Sarkissian et al., 2000; Cabib et al., 2003). PKU is a
group of recessively inherited metabolic disorders character-
ized by impaired conversion of L-Phe to tyrosine (Scriver
and Kaufman, 2001). In PKU and the related and less harm-
ful hyperphenylalaninaemia, an autosomal recessive gene
encodes phenylalanine hydroxylase with reduced or absent
enzymatic activity, resulting in abnormally high concentra-
tions of phenylalanine in body ﬂuids. The symptoms of PKU
manifest mainly in the brain. Early signs of PKU are mental
retardation, microcephaly and epilepsy. In the second or third
decadeoflifeaprogressivemotordisordersetsin(Pennington
et al., 1985; Scriver and Kaufman, 2001; Vallian et al., 2003).
High concentrations of phenylalanine are especially harmful
during early infancy. Untreated patients with PKU have lower
brain weights, changes in myelin structure and less developed
dendritic trees (Huttenlocher, 2000). Despite tremendous pro-
gress in the understanding of the molecular basis of PKU, the
mechanism(s) whereby hyperphenylalaninaemia results in
brain dysfunction are not known. We have recently demon-
strated that acute applications of L-Phe, at a range of con-
centrations found in the PKU brain, selectively depress
glutamatergic synaptic transmission in rat and mouse hippo-
campal and cerebrocortical cultured neurons by a combina-
tion of pre- and post-synaptic actions: (i) competition for the
glycine-binding site of the N-methyl-D-aspartate (NMDA)
receptors; (ii) attenuation of neurotransmitter release;
and (iii) competition for the glutamate-binding site of
(RS)-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) and kainate receptor subtypes (Glushakov et al.,
2002, 2003). In the PKU brain, glutamate receptors function
under conditions of chronic hyperphenylalaninaemia. If the
mechanisms that mediate the antiglutamatergic effects of
acute application of L-Phe in vitro are active in vivo in the
PKU brain, then chronic impairment in functioning of the
glutamate system could be evident at the level of glutamate
receptor density and expression.
Therefore,weusedacombinationofliquidchromatography–
tandem mass spectrometry (LC/MS/MS), patch-clamp,
radioligand binding and western blot approaches to investig-
ate the long-term changes at excitatory synapses in murine
PKU (Pah
enu2 mice).
Methods
All animal experiments were approved by the University of Florida
Animal Care and Use Committee.
Pah
enu2 mice
Two experimental groups were studied: (i) heterozygous and (ii)
homozygous Pah
enu2 (PKU) BTBR mice. Homozygous Pah
enu2
mice were produced by crossing homozygous Pah
enu2 fathers and
heterozygous Pah
enu2 mothers. Initial Pah
enu2 breeding pairs
(heterozygous females and homozygous males) were obtained
fromtheJacksonLaboratory(BarHarbor,ME,USA)andmaintained
as a colony under speciﬁc pathogen free (SPF) conditions. The mice
were on a normal (high L-Phe) diet and 6–10 weeks old at the time
they were killed. Homozygous mice are initially distinguished from
their heterozygous littermates by their lighter coat colour. The gen-
otype is conﬁrmed by determining concentrations of phenylalanine
in plasma by LC/MS/MS and restriction fragment lengthpolymorph-
ism analysis. The Pah
enu2 mutation creates a new Alw26I restriction
site in exon 7 (McDonald and Charlton, 1997). Genomic DNA was
extracted from blood samples and exon 7 of the Pah gene was
ampliﬁed using primers in introns 6 and 7. The resulting 220-bp
PCR product was then digested with Alw26I. The restriction frag-
ments were separated by electrophoresis on a 15% polyacrylamide
gel at 90 V for 2 h.
Liquid chromatography–tandem mass spectrometry
The concentration of L-Phe in brain tissues was determined using
LC/MS/MS (API 4000 LC/MS/MS system; Applied Biosystems,
Foster City, CA, USA). Mice were deeply anaesthetized with
Nembutal (80 mg/kg) and killed by cervical dislocation. Forebrains
were quickly dissected on ice, frozen in liquid nitrogen and stored at
 80 C. At the time of the experiment, brain tissue was homogenized
in de-ionized water (0.5% w/v) and centrifuged at 10 000 g for
15 min. Samples were prepared from 200 ml of the supernatant
together with 50 ml of 1.5 mM Phe-
13C5 as internal standard. Proteins
were precipitated with 800 ml of cold acidiﬁed acetonitrile (formic
acid, triﬂuoroacetic acid, acetonitrile, v/v/v 0.4:0.2:100). The sam-
ples were vortex-mixed for 30 s and centrifuged at 10 000 g for
10 min. The clear supernatant was evaporated to dryness at 40 . Dry
residueswerereconstitutedin200mlofde-ionizedwaterandaliquots
(25 ml) were injected into the LC/MS/MS equipment for further
analysis. Chromatographic separation was done on a C-18 column
(4.53100 mm, 3 mm particles, 24 C) using an isocratic
mobile phase (1 ml/l triﬂuoroacetic acid in 1 l H2O/acetonitrile,
93.1/6.9 v/v) at 0.6 ml/min. Detection was carried out in atmospheric
pressure chemical ionization mode by multiple reaction
monitoring of ion pairs mass/charge (m/z) 163.8/72.0 and m/z
170.1/152.6 for L-Phe and internal standard respectively.
Retention times were 3.45 min for both L-Phe and internal standard
inprocessedsamples.QuantitationofL-Phewasbasedoncalibration
curves generated by injecting known concentrations of L-Phe
and internal standard. Quality control samples were included in
every run.
Radioligand binding
On the day of the assay, tissue pellets were thawed in 5 mM Tris
buffer (pH 7.4), washed three times (40 000 g, 30 min, 4 C), and
resuspended in 5 mM Tris buffer. [
3H]MK-801 (ﬁnal concentration
2 nM) was used to selectively label the NMDA receptor complex.
Maximal activation of the NMDA receptor complex was assured by
the inclusion of 10 mM glutamate and 10 mM glycine. For saturation
binding assays, 200 ml aliquots of [
3H]MK-801-labelled membrane
(100–150 mg protein) were incubated in the absence or presence of
unlabelled MK-801 (0.6–25 nM) in a ﬁnal volume of 0.5 ml 5 mM
Tris buffer. Incubation time and temperature were 2 h and 25 C,
respectively. Non-speciﬁc binding, deﬁned as binding not displaced
by an excess (50 mM) of unlabelled MK-801, typically represented
<10% of total binding. Incubation was terminated by addition of
3 ml ice-cold buffer followed by vacuum ﬁltration through
Whatman GF/B glass-ﬁbre ﬁlters presoaked in 0.3% (w/v) poly-
ethyleneamine. Radioactivity trapped by the ﬁlters was determined
using a liquid scintillation counter. Each assay was conducted in
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 triplicate. The number of binding sites (Bmax) and the dissocia-
tion constant (Kd) were determined using the radioligand binding
analysis program GraphPad (v. 3.0; GraphPad Software, San Diego,
CA, USA).
Western blot analyses
For membrane protein extraction, 50 mg samples of frozen forebrain
tissue were rinsed twice with PBS, homogenized in 200 ml of extrac-
tion buffer (Mammalian Cell Lysis kit; Sigma, St Louis, MO, USA),
and incubated for 30 min on ice. Tissue homogenates were centri-
fuged at 15 000 g for 10 min at 4 C. The supernatant was collected
and stored at  80 C until the day of the experiment. The protein
concentration of samples was determined using the BSA Protein
Assay kit (Pierce, IL, USA). Protein concentrations were measured
in triplicate.
Western blot analysis was used to detect and quantify proteins of
interest. Membrane protein samples were heated to 100 C for 5 min
in loading buffer containing 60 mM Tris–HCl, 10% (v/v) glycerol,
2%(w/v)sodium dodecylsulphate (SDS),100mMdithiothreitoland
0.01% (w/v) bromophenol blue, pH 6.8. Individual samples contain-
ing 20 mg of protein in 30 ml of loading buffer were subjected to
electrophoresisonSDS–polyacrylamide7.5%(w/v)Tris–HClReady
Gel (Bio-Rad Laboratories, Hercules, CA, USA) using a Bio-Rad
Mini Protean apparatus. The protein samples were separated in the
presence of running buffer containing 15 mM Tris base, 115 mM
glycine and 0.06% (w/v) SDS, pH 8.3, at room temperature for 1.5 h
at 90 V. Protein transfer to nitrocellulose membrane (Hybond-ECL,
Amersham Biosciences, Little Chalfont, UK) was performed at 90 V
for 1.5 hin the presence ofice-cold transfer buffer containing 25 mM
Trisbase,192mMglycineand20%(v/v)methanol,pH8.3(Bio-Rad
Mini Trans Blot system). Membranes were then treated with primary
antibody at appropriate dilutions in PBST buffer with 5% milk over-
night at 4 C. The primary antibodies (Upstate, Lake Placid, NY,
USA) anti-Glu1, anti-Glu2/3, anti-NR2A, anti-NR2B and anti-
GABAA a1 receptor were used in concentrations of 0.125–1 mg/ml.
After washing three times in PBST buffer for 10 min, membranes
were treated for 1.5 h at room temperature with goat anti-rabbit
horseradish peroxidase secondary antibodies (Upstate, NY, USA)
diluted 1:10 000 in PBST buffer with 5% milk. Membranes were
washed as above, incubated in Supersignal West Pico Chemilumi-
nescent Substrate (Pierce) for 5 min at room temperature and
developed using Kodak BioMax XAR Film. Films were scanned
using Digital Imaging System FluoroChem (Alpha Innotech Cor-
poration, San Leonardo, CA, USA) and analysed (ImageJ v. 1.31;
WayneRasband, NationalInstitutesofHealth,Bethesda,MD,USA).
Western blot analysis for tissue samples from each animal for each
antibody treatment was repeated on three or four gels. The relative
optical density of each antibody treatment of tissue samples from
homozygous (PKU) animals with respect to the same antibody
treatment in heterozygous animals was calculated according to equa-
tion 1. First, the mean value of optical densities of tissue samples
from heterozygous animals was calculated for each antibody treat-
ment for each gel (equation 2). Secondly, the relative optical density
for each PKU tissue sample on separate gels was calculated by
dividing the optical density of each PKU tissue sample by the
mean optical density of tissue samples from heterozygous animals
for this particular gel. Thirdly, the mean values of relative optical
density for each PKU animal and for each antibody treatment was
calculated for all gels. Fourth, the mean 6 SEM value for all
PKU animals for each antibody treatment was calculated. Because
expression of GABA receptor a1 subunit was not signiﬁcantly
different between PKU and heterozygous mice, corrections for
variations in loading between wells were made by dividing the
equivalents for glutamate receptor subunits by the equivalents for
GABA receptor a1 subunit from the same well.
ROD ¼
1
nPKU
X nPKU
j¼1
1
nGel
X nGel
b¼1
PKUjb
Contrb
 !
ð1Þ
Contrb ¼
X nContr
k¼1
Contrkb ð2Þ
whereRODistherelativeopticaldensity,n
PKUisthenumberofPKU
animals, n
Gel is the number of gels, PKUi is a tissue sample from
a particular PKU animal, Contrb is the mean value for the tissue
samples from all heterozygous animals on gel b and k is the number
of tissue samples from heterozygous animals on gel b.
Neuronal cultures
Hippocampi were dissected from newborn rats, and treated with
0.25% trypsin to dissociate the cells using procedures previously
described (Glushakov et al., 2002). Cells were resuspended in
Neurobasal Medium containing B-27 serum-free supplement
(Invitrogen Life Technologies, Carlsbad, CA, USA),and were plated
in poly-L-lysine-coated 35 mm Nunc plastic tissue culture dishes
(1.5 3 10
6 cells/dish/2 ml medium).
Electrophysiological recordings
Whole-cell voltage-clamp recordings of membrane ionic currents
were conducted in neurons between 12 and 27 days in vitro as
previouslydescribed (Glushakovet al., 2002,2003).Thebasic extra-
cellular solution contained (in mM): NaCl 140, KCl 4, CaCl2 2,
MgCl2 1, 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid
(HEPES) 10, and glucose 11. The pH of the extracellular solution
was adjusted to 7.4 using NaOH. The main solution for ﬁlling the
patch electrodes contained (in mM): Cs gluconate 135, NaCl 5,
KCl 10, MgCl2 1, CaCl2 1, Ethylene glycol-bis(2-aminoethylether)-
N,N,N0,N0-tetraacetic acid (EGTA) 11, HEPES 10, Na2ATP 2, and
Na2GTP0.2mM.ThepHoftheintracellularsolutionwasadjusted to
7.4 using CsOH. The experiments were performed at room tempera-
ture (22–23 C) at a holding potential (VH)o f 30 mV, and the
extracellular solutions contained Mg
2+.I NMDA was recorded in
response to a 6 s period of NMDA application. Various concentra-
tions of NMDA, glycine and L-Phe were added to the extracellular
solution according to the protocols described below. All compounds
were purchased from Sigma. Current data were digitized on-line
and analysed off-line using the software program pClamp9 (Axon
Instruments, Foster City, CA, USA).
General data analysis
Values are reported as mean 6 SEM. Prior to parametric testing,
the assumption of normality was validated using the Kolmogorov–
Smirnov test with Lilliefor’s correction (SSPS v. 10; SPSS, Chicago,
IL, USA). Multiple comparisons among groups were analysed using
analysis of variance (two- or one-way repeated measures with two-
or one-way replication where appropriate) followed by Student–
Newman–Keuls testing. Single comparisons were analysed using
a two-tailed Student’s t test. P < 0.05 was considered signiﬁcant.
Glutamate receptors in phenylketonuria Page 3 of 8
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 Results
Consistentwiththegeneticdefect,Pah
enu2BTBRmiceexhib-
ited increased concentrations of L-Phe. Brain concentrations
of L-Phe in homozygous Pah
enu2 mice were almost six times
higher than those in their heterozygous counterparts (Fig. 1).
It is interesting that concentrations of L-Phe in the forebrains
of heterozygous Pah
enu2 mice were slightly higher than those
in wild-type BTBR mice reported in the literature (Sarkissian
et al., 2000).
To verify whether L-Phe inhibits glutamate receptor func-
tion at the range of concentrations found in the Pah
enu2 mouse
brain, we determined concentration–response relationships
for glycine to activate INMDA in the presence of different
concentrations of L-Phe (0, 1, 3, 10 and 30 mM). Increasing
concentrations of L-Phe caused a parallel shift of the concen-
tration–response relationship for glycine to activate INMDA
towards greater concentrations of glycine (Fig. 2). At the
same time, L-Phe neither decreased the maximal glycine-
induced activation of INMDA nor altered the slope of the
concentration–responserelationships.Analysisofthe concen-
tration–response relationships by Schild regression yielded a
linear response with a slope of 1.09 and an equilibrium
constant (KB) of 573 mM. These ﬁndings are consistent
with competitive antagonism of L-Phe at the glycine-binding
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Fig. 1 Measurement of the brain concentration of phenylalanine in heterozygous (+/ ) and homozygous ( / ) Pah
enu2 mice using
LC/MS/MS. (A) Continuous bold lines represent the typical examples of the negative ion scan LC/MS/MS spectrum of phenylalanine
extracted from the brain tissues of heterozygous (weight of the sample 38.6 mg) and Pah
enu2 (weight of the sample 37 mg) mice,
respectively. The narrow lines correspond to the multiple reaction monitoring pair of m/z 170.1 (parent ion) and m/z 152.6 (product ion) for
the internal standard (
13C5 L-Phe). (B) Bar graphs showing the concentration of phenylalanine, measured in the forebrain of heterozygous
(+/ ) and homozygous ( / ) Pah
enu2 mice. Data are means 6 SEM of four to six brain samples. ( / ) versus (+/ ): *P < 0.01.
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Fig. 2 Inhibition of the NMDA (1 mM)-activated current by L-Phe. (A) Concentration–response curves to glycine (Gly) were carried out in
rat cultured hippocampal neurons in the absence and presence of L-Phe (concentrations noted in ﬁgure). Peak INMDA was normalized to
INMDA recorded at 10 mM Gly in the absence of L-Phe and plotted against the concentration of glycine [Gly]. Endogenous Gly in primary
neuronal cultures explains the non-zero INMDA in the absence of added Gly. (B) Dose ratios (dr) were calculated from [Gly] producing equal
responses (60% of activation) in the presence of L-Phe divided by [Gly] with the same response obtained without L-Phe. These dr(s) were
then applied to the Schild equation: log (dr-1) = log [L-Phe]   log KB, where KB is the equilibrium dissociation constant for L-Phe.
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 site of the NMDA receptor. Given that the glycine-binding
site of the NMDA receptors within a synapse is typically not
saturated (Bergeron et al., 1998), L-Phe may effectively
attenuate NMDA receptor function in the PKU brain.
Together with the previously reported IC50 of 0.98 mM for
L-Phe to attenuate non-NMDA receptor function in cultured
neurons (Glushakov et al., 2003), these results suggest that
endogenous L-Phe may effectively depress glutamatergic
synaptic transmission in the Pah
enu2 mouse brain.
IfL-Phedepressesglutamate receptor function invivo,then
chronic exposure to high levels of endogenous L-Phe should
cause long-term changes in glutamate receptor density and
expression. In order to test this hypothesis, receptor density
and receptor subunit composition were studied by radioligand
binding using [
3H]MK-801 and by western blot analyses,
respectively. The forebrain tissue used in these experiments
was isolated from the same homozygous and heterozygous
Pah
enu2 mice in which measurement of brain concentration of
L-Phe was performed. The maximum binding (Bmax) and
afﬁnity (KD) data for [
3H]MK-801 binding sites of mouse
forebrain for the two groups are presented in Fig. 3. The
maximumbindingfor [
3H]MK-801(NMDA receptordensity)
was signiﬁcantly greater in homozygous PKU mice than in
heterozygous littermates (P < 0.005), whereas the afﬁnity for
the radioligand was not different between these groups
(P = 0.1). These ﬁndings are consistent with compensatory
up-regulation of NMDA receptors in the presence of the com-
petitive antagonist L-Phe. In agreement with the radioligand
binding data, expression of the NR2A subunit of the NMDA
receptors in the forebrain of homozygous Pah
enu2 mice was
signiﬁcantly increased compared with that of heterozygous
Pah
enu2 mice. Surprisingly, the expression of NMDA receptor
NR2B subunits was diminished in PKU mice (Fig. 4A, B).
In neuronal cultures, acute application of L-Phe also
signiﬁcantly depresses glutamate release and functioning of
non-NMDA glutamate receptors, but does not affect activity
of GABA receptors (Glushakov et al., 2003). Therefore, it is
plausible to expect that L-Phe, by depressing non-NMDA
glutamate receptor functioning, may elicit a compensatory
change in expression of these receptors in vivo in the PKU
brain. GABA receptors, on the other hand, should be less
affected during PKU. In order to test these possibilities, a
western blot analysis of GluR1 and GluR2/3 subunits of
AMPA receptors and a1 subunits of GABA receptors was
performed. Consistent with the functional effects of L-Phe on
non-NMDA glutamate receptors and GABA receptorsin vitro
(Glushakov et al., 2003), the expression of both GluR1 and
GluR2/3 subunits was signiﬁcantly increased in homozygous
Pah
enu2 mice (Fig. 4A, B), whereas the expression of GABA
receptor a1 subunit was not different in the homozygous and
heterozygous mice (Fig. 4C).
Discussion
The results obtained indicate that glutamatergic synaptic
transmission in the hyperphenylalaninaemic PKU brain has
undergone marked alterations. There is much in vitro, in vivo
and clinical evidence that abnormal glutamatergic synaptic
transmission contributes to a variety of brain disorders,
which are phenotypically similar to those observed in
PKU (e.g. cognitive impairment, seizures, microcephaly).
Thus, the observed changes in the glutamatergic system
in the Pah
enu2 mouse brain provide new insights into the
understanding of the cellular mechanisms that may mediate
PKU-speciﬁc brain disorders.
Identiﬁcation of the major causes of brain dysfunctions in
PKU and an understanding of the cellular mechanisms that
mediate these dysfunctions rely heavily on precise measure-
ments of phenylalanine concentrations in the brains of PKU
subjects. Measurements in early-treated patients indicate that,
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 following an oral load, the L-Phe concentration varies and
may increase up to as much as 0.8 mM (Moller et al., 2003).
Several lines of evidence suggest that the available measure-
ments of brain phenylalanine concentration in PKU patients
may be an underestimation (Pietz et al., 1999; Weglage et al.,
2002). The difﬁculties of measuring brain phenylalanine
concentrations in PKU patients are essentially overcome in
Pah
enu2 (PKU) mice. By using these laboratory animals, age,
genetic, dietary and other experimental conditions can be
controlled. In addition, the variability of the results obtained,
due to insufﬁcient signal-to-noise ratios, can be signiﬁc-
antly diminished by performing steady-state measurements.
Indeed, we found that brain concentrations of phenylalanine
in all homozygous PKU mice were markedly increased and in
agreement with concentrations reported by others (Sarkissian
et al., 2000; Joseph and Dyer, 2003). This concentration of
phenylalanine is close to the IC50 for L-Phe for depressing the
frequency of AMPA/kainate receptor-mediated mEPSCs
(980 6 130 mM) (Glushakov et al., 2003) and substantially
higher than the KB of L-Phe to compete for the glycine-
binding site of NMDA receptors (576 mM; Fig. 2). The
changes in glutamatergic but not GABAergic transmission
in PKU mice are in agreement with the depressant effect
of L-Phe on glutamate receptor function and neurotransmitter
release in the neuronal cultures (Glushakov et al., 2002,
2003), and correlate with the signiﬁcant increase in brain
concentration of phenylalanine in the same animals measured
by LC/MS/MS (Fig. 1). These ﬁndings, together with the
Fig. 4 Changes in protein expression of NMDA receptor NMR2A and NR2B and AMPA receptor Glu1 and Glu2/3 subunits in the forebrain
of homozygous (PKU) Pah
enu2 mice. (A) Representative western blot (WB) images of NMR2A, NR2B, Glu1 and Glu2/3 subunits in the
forebrain of homozygous and heterozygous Pah
enu2 mice to illustrate band intensities. The left-hand set is from forebrain tissue isolated
from heterozygous (+/ ) mice and the right-hand set is from the same brain area isolated from homozygous ( / ) Pah
enu2 mice.
Western blots for all receptor subunits were performed on forebrain tissue isolated from the same heterozygous and homozygous mice.
(B) Histogram showing results of the densitometric analysis of western blots for NMR2A, NMR2B, Glu1 and Glu2/3 subunits. Densities of
NMR2A, NMR2B, Glu1 and Glu2/3 blots from heterozygous mice were taken as 100%. (C) The results of western blot analysis for the a1
subunit of GABAA receptor isolated from the same heterozygous and homozygous mice as for NMDA receptor NMR2A and NR2B and
AMPA receptor Glu1 and Glu2/3 subunits. Data are means 6 SEM of four to six brain samples. ( / ) versus (+/ ): *P < 0.01;
#P < 0.05.
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 fact that the non-tyrosine metabolites of phenylalanine,
at PKU-relevant concentrations, do not affect glutamatergic
synaptic transmission in neuronal cultures (Glushakov et al.,
2003), indicate that elevated L-Phe is probably a major cause
of the changes in the glutamatergic system in the PKU brain
observed inthisstudy.It isimportant tostress thatL-Phe itself
is probably a major cause of brain dysfunction in PKU.
Thus, PKU-speciﬁc neurological symptoms can largely be
prevented by a strict diet that is low in phenylalanine, but
not a relaxed diet containing elevated concentrations of
tyrosine (Scriver and Kaufman, 2001).
The alteration in glutamate receptors in the PKU brain has
been found at the level of NMDA receptor binding and of
NMDA and AMPA receptor subunit expression. In particular,
consistent with the depressant effect of L-Phe on glutamate
receptor function in neuronal cultures, receptor binding
experiments showed signiﬁcant up-regulation of NMDA
receptor density in PKU mice. The expression of NMDA
receptor NR2A subunit and AMPA receptor subunits Glu1
and Glu2/3 were also signiﬁcantly increased. In contrast,
expression of the NR2B subunit was decreased. These differ-
ential changes in expression of NMDA receptor subunits
NR2A and NR2B in the PKU mouse brain may be explained
by the mechanism whereby L-Phe depresses NMDA receptor
function. L-Phe competes for the glycine-binding site of
NMDA receptors (Fig. 2) (Glushakov et al., 2002, 2003).
The potency of glycine as a co-agonist at expressed
NMDA receptors has been shown to be as much as 10-fold
higher for receptors containing NR2B subunits than for those
containing NR2A subunits (Priestley et al., 1995). Similarly,
Kew and colleagues showed that NMDA receptors in cortical
neurons of young rats, which express a relatively greater
amount of NR2B, had higher afﬁnity for glycine than recep-
tors inneurons ofolder rats(Kew et al.,1998). BecauseL-Phe
is a relatively weak antagonist of NMDA receptors at the
glycine binding site, it is likely to depress more potently
NMDA receptors containing NR2A subunits that have
lower afﬁnity for glycine. Greater depression by L-Phe of
NR2A-containing NMDA receptors would cause a greater
compensatory reaction, which would result in an increased
expression of NR2A-containing NMDA receptors. In condi-
tions of permanent depression of NR2A-containing NMDA
receptors, the relative contribution of NR2B-containing
receptors may increase. This may cause a compensatory
decrease in NR2B receptor expression. During CNS devel-
opment the NR2B subunit is more highly expressed in the
embryonic and neonatal brain, and expression of the NR2A
subunit increases as the brain matures (Watanabe, 1996). The
increase in NR2A/NR2B proportion represents premature
‘ageing’ ofNMDAreceptorsinthePKUbrain,andmayresult
in altered pharmacological and functional proﬁles of the
NMDA system in the PKU brain. In particular, Tang and
colleagues demonstrated that overexpression of NMDA
receptor 2B in the forebrains of transgenic mice leads to
enhanced learning ability and memory with respect to
wild-type mice (Tang et al., 1999). Therefore, we may
speculate that the decrease in NMDA NR2B receptor expres-
sion in the PKU brain may contribute to PKU-speciﬁc
impairment of learning and memory.
It has been reported that the brain concentration of glycine
in PKU infants is less than 17% of normal (Quentin et al.,
1974a). The cerebrospinal ﬂuid glycine concentration of
older PKU children and adults was within the normal
range (Quentin et al., 1974a, b). Therefore, NMDA receptor
function can be more severely depressed by L-Phe in the
brains of young PKU subjects, whereas this effect of L-Phe
islessenedlateroninlife.AgreaterdepressanteffectofL-Phe
on NMDA receptor function in the developing brain would
be in an agreement with the observed greater damage caused
by hyperphenylalaninaemia during early infancy in PKU
(Scriver and Kaufman, 2001).
Our preliminary unpublished observations indicate that,
despite the compensatory up-regulation of glutamatergic
synaptic transmission in the continued presence of elevated
concentrations of L-Phe, the total functional response of
glutamate receptors inthe PKU brain is still depressed. There-
fore, the pathophysiological changes produced by chronic
L-Phe exposure could involve effects induced by both expo-
sure to and withdrawal of L-Phe. For example, we hypo-
thesize that a combination of factors may occasionally lead
to potentiation of glutamate receptor activity and the genera-
tion of epileptic activity, one of the brain-related disorders in
PKU. These factors include: (i) increase in expression and
density of glutamate receptors during chronic exposure to
L-Phe; (ii) increase in concentrations of glycine in the
brain of non-infant PKU patients; and (iii) a decrease in
the brain concentration of L-Phe caused by variations in
diet and/or age-dependent changes (withdrawal effect).
The alterations in the expression and function of NMDA
and AMPA receptors in the developing hyperphenylalaninae-
mic brain may have a substantial impact on synaptic plasticity
and brain function. The impairment of glutamate receptor
activity by L-Phe may explain the observation that untreated
patients with PKU have lower brain weights, reduced dendri-
tic arborization and decreased numbers of dendritic spines
(Huttenlocher, 2002). The cellular mechanisms of brain dis-
orders characteristic of PKU are probably complex and multi-
faceted. Speciﬁc investigation of the role of L-Phe-induced
alterations in glutamatergic synaptic transmission in the func-
tional and morphological plasticity of synapses, involving the
dopaminergic and other systems, and in the behavioural
changes of PKU mice should advance understanding of
this phenomenon and of the roles of glutamatergic synaptic
transmission in brain functioning.
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